# US 10,501,492 B2 · Antibiotic compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,501,492 B2
- Document ID: US10501492B2
- Status: Granted
- Kind: B2
- Application number: 13/393,294
- Filed: 2010-08-31
- Published: 2012-06-21
- Granted: 2019-12-10
- Earliest claimed: 2009-09-02
- Assignees: National Centre for Polar and Ocean Research (NCPOR); Foundation for Neglected Disease Research (FNDR)
- Applicants: Prabhu Dutt Mishra; Girish Badrinath Mahajan
- Inventors: Prabhu Dutt Mishra; Girish Badrinath Mahajan
- Web page: https://patentgrep.com/patent/US10501492B2

## CPC

- A61P 31/04: Antibacterial agents
- C07K 5/10: Tetrapeptides
- C07D 513/18: Bridged systems
- C07K 5/101: {the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Purified compounds of formula I are described. Compounds include all stereoisomeric forms and all tautomeric forms of the compounds of formula I and pharmaceutically acceptable salts and derivatives. Processes for the production of the antibacterial compounds by fermentation of the microorganism belonging to Streptomyces species (PM0626271/MTCC 5447) and to pharmaceutical compositions containing one or more of the novel compounds as active ingredient and their use in medicines for treatment and prevention of diseases caused by bacterial infections are described.

## Claims

### Claim 1

A process for the production of pharmaceutically acceptable salt of compound of Formula I(a) or pharmaceutically acceptable salt of compound of Formula I(b)
comprising the steps of:
(a) cultivating the microorganism Streptomyces species (PM0626271/MTCC 5447) under submerged aerobic conditions in a nutrient medium containing sources of carbon, nitrogen and inorganic salts at a temperature ranging from 26° C. to 36° C. and a pH of 6.5 to 8.5 for 24 hours to 96 hours at 60 revolutions per minute (rpm) to 140 rpm and 100 litres per minute (lpm) aeration to produce the compound of Formula I(a) and the compound of Formula I(b) in the fermented broth;
(b) isolating the compound of Formula I(a) and the compound of Formula I(b) from the fermented broth obtained after cultivating the microorganism Streptomyces species (PM 0626271/MTCC 5447);
(c) purifying the isolated compound of Formula I(a) and the isolated compound of Formula I(b); and
(d) converting the purified compound of Formula I(a), or the purified compound of Formula I(b) prepared in step (c) to its pharmaceutically acceptable salt.